In 2010, the world’s most expensive therapy was Soliris (eculizumab), costing around USD 409,500 p...
Read moreFive success pillars — your JCA evidence-generation checklist From 12th January 2025, the Eu...
Read moreA €3 million invoice for a single infusion can dazzle as easily as it alarms. Gene therapies such ...
Read moreProving the long-term value of pharmaceutical assets remains one of the biggest challenges for manuf...
Read moreThe recent Medicines and Healthcare products Regulatory Agency (MHRA) approval of the Alzheimer’s ...
Read moreThe Joint Clinical Assessment (JCA), a core feature of the Regulation (EU) 2021/2282, aims to stream...
Read moreBiotech and pharmaceutical companies routinely spend tens of millions in clinical trials; however, p...
Read moreFor decades, the free market model of the US healthcare system has been very attractive for biotech ...
Read moreThe vast majority of products launching in the UK will be assessed by the National Institute for Hea...
Read moreDecisions regarding National Institute for Health and Care Excellence (NICE) appraisals are not made...
Read more